Aligos Therapeutics (NASDAQ:ALGS) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Aligos Therapeutics (NASDAQ:ALGS) in a report released on Friday, Benzinga reports. They currently have a $75.00 price objective on the stock.

Aligos Therapeutics Stock Down 10.2 %

ALGS opened at $9.14 on Friday. The stock’s 50 day moving average price is $13.19 and its two-hundred day moving average price is $16.19. The firm has a market capitalization of $713.93 million, a P/E ratio of -7.14 and a beta of 2.18. Aligos Therapeutics has a 12-month low of $8.70 and a 12-month high of $30.00.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.00) by $4.75. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. The business had revenue of $1.06 million for the quarter. During the same quarter in the previous year, the business posted ($10.75) EPS. As a group, analysts anticipate that Aligos Therapeutics will post -8.15 earnings per share for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Armistice Capital LLC acquired a new stake in shares of Aligos Therapeutics during the 4th quarter worth approximately $4,538,000. Opaleye Management Inc. bought a new stake in Aligos Therapeutics in the 4th quarter valued at $861,000. Acadian Asset Management LLC raised its stake in shares of Aligos Therapeutics by 17.6% in the 1st quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock valued at $644,000 after buying an additional 98,628 shares in the last quarter. Finally, Altitude Crest Partners Inc. bought a new position in shares of Aligos Therapeutics during the 4th quarter worth about $1,889,000. 60.43% of the stock is currently owned by institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).